Navigation Links
DIA Conference to Focus on Clinical Trial Disclosure and the Importance of Transparency
Date:9/10/2013

HORSHAM, Pa (PRWEB) September 10, 2013

The DIA conference Clinical Trial Disclosure: Towards a More Transparent World will provide guidance on potential implications of the transparency of clinical trial information in registration, reporting and more. The meeting, to be held Oct. 1 to 2 in Bethesda, Md., will bring together academics, government regulators and patient advocates to provide key guidance on:

  •     Requirements for clinical trial disclosure in the United States and the European Union
  •     The interaction among medical writing, regulatory affairs and clinical trial disclosure to maintain consistency for protocol registration and the reporting of results
  •     The impact of greater transparency in clinical trial disclosure on industry and academia
  •     The advantages and implications of the availability of clinical trial disclosure databases

“The continuing proliferation of national and industry-sponsored registries leaves many sponsors considering disclosure strategy, developing operational measures and looking for efficient ways to manage dissemination of clinical trial protocol information. We are excited to bring together these leaders to discuss moving the needle in clinical trial disclosures,” said Susan Cantrell, director of DIA North America.

Speakers include:

  •     Jarilyn Dupont, director of regulatory policy, Food and Drug Administration
  •     Mark Barnes, partner, Ropes & Gray LLP
  •     Chris Galvin, analyst, Office of Inspector General, U.S. Department of Health and Human Services
  •     Jessica B. Gilbart, president and CEO, DC/MD/VA Chapter, Lupus Foundation of America
  •     Christine Laine, M.D., editor, Annals of Internal Medicine, and senior vice president, American College of Physicians
  •     Joseph Solomon Ross, M.D., assistant professor of medicine (general medicine) and of public health (health policy), Yale School of Medicine
  •     Michael Krumenacker, M.D., publication compliance officer, Sanofi

To find out more about the event and to register, visit DIA’s website for Clinical Trial Disclosure: Towards a More Transparent World.

ABOUT DIA: DIA is a neutral, global, professional and member-driven association of nearly 18,000 professionals involved in the discovery, development and life cycle management of pharmaceuticals, biotechnology, medical devices and related health care products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well-being worldwide. Headquarters are in Horsham, Pa., USA, with offices in Basel, Switzerland; Tokyo, Japan; Mumbai, India; Beijing, China; Washington, D.C.; and Latin America. Visit our website at http://www.diahome.org and follow DIA at: LinkedIn, Twitter, YouTube, Facebook, Flickr and Pinterest.

###

Read the full story at http://www.prweb.com/releases/2013/9/prweb11109637.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Elsevier organizes label-free technologies conference
2. NJ stroke researchers report advances in spatial neglect research at AAN Conference
3. Blending conference translates substance abuse research into practice
4. International conference to explore health of descendants of transatlantic slave trade
5. Dr. Yael Mosse will receive first Nachman Award in Pediatric Oncology at national conference
6. Nobel laureate to keynote international pharmaceutical conference at URI
7. Pharmica Consulting to Hold HIT Conference for the Pharmaceutical Industry
8. Snoring Isn't Sexy Member Dr. Mark Levy attends Academy of Clinical Sleep Disorders Disciplines Conference in Phoenix, Arizona
9. AuntMinnie Begins Live Video Stream of ISCT Conference Proceedings
10. NOVAtime Solutions to be showcased at Booth #1821 in the upcoming Society for Human Resource Management (SHRM) Annual Conference and Exposition
11. International Nanomedicine Conference bound for Sydney: July 2-4, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, the ... affiliation with Tennessee Counseling Association. This new relationship allows TherapySites to ... Counseling Association, adding exclusive benefits and promotional offers. , "TCA is extremely excited ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star ... , Millions of individuals in the United States and Canada wear eyeglasses. Once considered ... both correct vision and make a fashion statement. Even celebrities use glasses as a ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, ... editors can give their videos a whole new perspective by using the title ... Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to choose ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
Breaking Medicine Technology: